Select Premarket Movers
Upside
– $BKYI +76% (no clear fresh catalyst identified; unusually large, high-volume premarket move)
– $SSTI +51% (agrees to be acquired for $8.00 cash plus a contingent-value right worth up to another $3.00 per share)
– $SANG +39% (agrees to a $204M cash-and-stock takeover at an indicated 47% premium)
– $SMMT +18% ($2B strategic equity investment at an $18.36-equivalent share price plus an expanded oncology collaboration)
– $MSGY +15% (rebounds after the financing-driven selloff; $1M placement proceeds will fund a further acquisition)
– $FFAI +13% (no clear fresh catalyst identified; unusually large, high-volume premarket move)
– $MX +8.7% (rises on read-through from its strategic partner’s U.S. government silicon-carbide development award)
– $NVTS +8.7% (awarded a U.S. government program to develop next-generation 10-kV silicon-carbide power semiconductors)
– $IOVA +8.3% (no clear fresh catalyst identified after a clinical and regulatory-news check; unusually large, liquid biotech move)
– $KMX +5.6% (Q2 beat across the board as sales and profit topped expectations)
Downside
– $QURE -52%, CLPT -24% (FDA said the AMT-130 data package was inadequate to support accelerated approval in Huntington’s disease; CLPT falls on delivery-platform read-through)
– $JLHL -31% ($898K private placement includes shares and pre-funded warrants priced at $0.30, implying substantial dilution)
– $FICO -21%, EFX -4.0% (credit-data names fall as FHFA pushes broader VantageScore use and moves to weaken FICO’s mortgage-scoring monopoly)
Position: None
